Business
Nuwellis Completes Acquisition of Rendiatech
Adds automated kidney function monitoring technology to support earlier clinical insight and strengthen Nuwellis’ fluid management platform MINNEAPOLIS, March
About this update from Nuwellis, Inc.
[{"type":"text","content":"Adds automated kidney function monitoring technology to support earlier clinical insight and strengthen Nuwellis’ fluid management platform\nMINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd. following its bankruptcy proceedings; the Company purchased Rendiatech primarily to gain access to such assets. The purchase expands Nuwellis’ capabilities across the cardiorenal continuum by adding diagnostic monitoring technology that complements the company’s Aquadex SmartFlow® System, which is designed to remove excess fluid in patients experiencing fluid overload. Continuous renal monitoring is an important clinical tool for assessing kidney function and acute kidney injury (AKI) in critically ill patients. Rendiatech’s technology enables automated, continuous renal monitoring with real-time data capture, replacing manual collection and intermittent readings. The platform provides clinicians with timely insights that can support earlier intervention and establishes a foundation for future expansion into advanced renal analytics and broader kidney function assessment. “With the addition of Rendiatech, we are expanding Nuwellis’ ability to support clinicians managing complex fluid balance conditions and acute kidney injury risk,” said John Erb, Chief Executive Officer of Nuwellis. “By combining real-time kidney function monitoring with targeted fluid removal, we are strengthening our role in helping hospitals identify patients earlier and manage fluid balance more precisely.” “Urine output is a critical indicator of kidney function and fluid balance in hospitalized patients,” said Stuart Goldstein, MD, Nuwellis’ Director of Clinical Strategy and Director of the Center for Acute Care Nephrology at Cincinnati Children’s Hospital Medical Center. “Automated monitoring that provides continuous, reliable data can improve the accuracy and consistency of this measurement, helpin...